Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Current Therapeutic Strategies and Future Perspectives for the Treatment of Venous Thromboembolism

Author(s): David A. Garcia

Volume 16, Issue 31, 2010

Page: [3475 - 3477] Pages: 3

DOI: 10.2174/138161210793563347

Price: $65

Abstract

Pulmonary embolism (PE) and deep vein thrombosis (DVT) are widely regarded as manifestations of a single disease, venous thromboembolism (VTE). An evidence-based approach to the treatment of acute VTE will be reviewed here. Currently available therapeutic options will be emphasized; possible future treatment approaches will be discussed briefly. The chronic management of VTE involves assessment of the risks and benefits of prolonged anticoagulation and is discussed in more detail elsewhere in this issue.

Keywords: Venous thromboembolism, anticoagulation, thrombolysis, Pulmonary embolism, deep vein thrombosis, vitamin K antagonists, rapid-acting gly-cosaminoglycan agent, fondaparinux, low molecular weight heparin, thrombolytic therapy, activated partial throm-boplastin time, idiopathic VTE, Systemic Thrombolysis, Pulmonary Embolectomy, Dalteparin, Enoxaparin, Tinzaparin, Inferior Vena Cava Interruption, craniotomy, caval thrombosis, DVT, tPA-induced bleeding, thrombotic syndrome, Statins, HmGCoA Reductase inhibitors, C-reactive protein, Aspirin, arterial thrombotic events, myocardial infarction, VKA-based anticoagulation, warfarin


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy